TG THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$616M
Cost of Revenue
$101M
R&D
$160M
SG&A
$232M
D&A
$59K
Operating Income
$123M
EBITDA
$123M
Interest Expense
$27M
Other Income/Expense
$11M
Pretax Income
$107M
Tax Provision
$-340M
Net Income
$447M
Operating Margin
20.0%
Net Margin
72.6%
Effective Tax Rate
-316.4%
Deferred Tax Assets
$348M
DTA Valuation Allowance
$40M
Tax Credit Carryforwards
$58M
NOL Carryforwards
$276M
ETR (Continuing Operations)
-316.4%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-6.0%
Operating Lease Cost
$2M
Revenue YoY Variation
87.3%
Income YoY Variation
194.1%